Floatz logo

gi-4000

Prostate Cancer

University Hospital, Basel, SwitzerlandvaccineN/ADormant
D
25/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
59/ 100

Competitive context

427 Active assets in the Prostate Cancer cohort.

Asset / SponsorPhaseRating
Degarelix
Bayer
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB
Flotufolastat F-18
Washington University School of Medicine
Phase 4BB
Estramustine
The University of Texas Health Science Center, Houston
Phase 3BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

gi-4000 is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
malignant pancreatic neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →